![Morad El Gueddari](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenienza dei contatti di primo grado di Morad El Gueddari
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Yposkesi
![]() Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021.
5
| Subsidiary | Biotechnology | 5 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Morad El Gueddari tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal | |
EUROFINS CEREP | Miscellaneous Commercial Services | Director/Board Member | |
Imperial College London | College/University | Graduate Degree | |
École Centrale Paris | College/University | Undergraduate Degree | |
Ecole Polytechnique | College/University | Undergraduate Degree | |
GETLINK SE | Railroads | Public Communications Contact | |
Lundbeck SAS
![]() Lundbeck SAS Pharmaceuticals: MajorHealth Technology Lundbeck SAS is a pharmaceutical laboratory, which focuses on neurology and psychiatry. The company was founded in 1992 and is headquartered in Paris La Defense, France. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Institut d’Études Politiques de Toulouse | College/University | Graduate Degree | |
Genethon
![]() Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Biotechnology | Chief Executive Officer | |
Hera Diagnostics SAS | Corporate Officer/Principal | ||
AFYREN | Biotechnology | Director of Finance/CFO | |
Carbiolice SAS
![]() Carbiolice SAS Miscellaneous ManufacturingProducer Manufacturing Carbiolice SAS engages in the provision of biological technologies for plastics and synthetic fibers. The company was founded on June 14, 2016 and is headquartered in Riom, France. | Miscellaneous Manufacturing | Director/Board Member | |
Evertree SAS
![]() Evertree SAS Chemicals: SpecialtyProcess Industries Evertree SAS produces plant-based chemicals. Its product SynerXiD is a family of proprietary, dry powder chemicals for industrial manufacturing. The company was founded by Anthony Parker and Joe Marcinko on February 16, 2016 and is headquartered in Compiegne, France. | Chemicals: Specialty | Director/Board Member | |
Atamyo Therapeutics SAS
![]() Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | Biotechnology | Chairman |
Statistiche
Distribuzione geografica
Francia | 16 |
Regno Unito | 2 |
Settori
Health Technology | 7 |
Consumer Services | 6 |
Commercial Services | 2 |
Transportation | 2 |
Producer Manufacturing | 2 |
Posizioni
Director/Board Member | 8 |
Chief Executive Officer | 3 |
Corporate Officer/Principal | 3 |
Undergraduate Degree | 2 |
Chairman | 2 |
Contatti più connessi
- Borsa valori
- Insiders
- Morad El Gueddari
- Connessioni Società